NASDAQ:MDVL

MedAvail Stock Forecast, Price & News

$11.40

+0.54 (+4.97 %)

(As of 05/14/2021 01:20 PM ET)

Add

Compare

Today's Range

$11.06

▼

$11.40

50-Day Range

$11.50

▼

$15.03

52-Week Range

$9.00

▼

$46.20

Volume299 shs

Average Volume88,184 shs

Market Capitalization$364.18 million

P/E RatioN/A

Dividend YieldN/A

Beta1.2

30 days | 90 days | 365 days | Advanced Chart

Receive MDVL News and Ratings via Email

Sign-up to receive the latest news and ratings for MedAvail and its competitors with MarketBeat's FREE daily newsletter.

About MedAvail

MedAvail Holdings, Inc. operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations. It also operates SpotRx, a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery. MedAvail Holdings, Inc. is based in Mississauga, Canada.

MedAvail Holdings' (MDVL) CEO Ed Kilroy on Q1 2021 Results - Earnings Call Transcript
May 14, 2021 | seekingalpha.com

MedAvail (NASDAQ:MDVL) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
May 13, 2021 | americanbankingnews.com

MedAvail (NASDAQ:MDVL) Releases FY 2021 Earnings Guidance
May 12, 2021 | americanbankingnews.com

MedAvail Reports First Quarter 2021 Financial Results
May 12, 2021 | finance.yahoo.com

MedAvail (MDVL) Set to Announce Quarterly Earnings on Wednesday
May 5, 2021 | americanbankingnews.com

MedAvail to Report 2021 First Quarter Financial Results on May 12, 2021
April 28, 2021 | finance.yahoo.com

MedAvail (NASDAQ:MDVL) Updates FY 2021 Earnings Guidance
April 28, 2021 | americanbankingnews.com

Brokerages Anticipate MedAvail Holdings, Inc (NASDAQ:MDVL) to Post -$0.30 EPS
April 27, 2021 | americanbankingnews.com

MedAvail Announces Continued Expansion of Its Technology Agreement With a North Texas Health System
April 14, 2021 | finance.yahoo.com

18,003
March 31, 2021 | businesswire.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MDVL

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.medavail.com

Phone905-812-0023

Employees137

Year FoundedN/A

Sales & Book Value

Annual Sales$1.03 million

Price / Sales353.58

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.54 per share

Price / Book7.40

Profitability

EPS (Most Recent Fiscal Year)($5.52)

Net Income$-4,260,000.00

Net Margins-245.38%

Return on Equity-168.39%

Return on Assets-104.11%

Debt

Debt-to-Equity Ratio0.15

Current Ratio2.71

Quick Ratio1.11

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares31,946,000

Market Cap$364.18 million

Next Earnings Date8/4/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.88 out of 5 stars

Medical Sector

120th out of 2,039 stocks

Pharmaceutical Preparations Industry

47th out of 769 stocks

3.5 Analyst's Opinion

Consensus Rating
MedAvail has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.00, MedAvail has a forecasted upside of 84.2% from its current price of $10.86.
Amount of Analyst Coverage
MedAvail has only been the subject of 1 research reports in the past 90 days.

3.6 Community Rank

Outperform Votes
MedAvail has received 5 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MedAvail has received 2 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MedAvail has received 71.43% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MedAvail and other stocks. Vote “Outperform” if you believe MDVL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDVL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MedAvail does not currently pay a dividend.
Dividend Growth
MedAvail does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MedAvail insiders have not sold or bought any company stock.
Percentage Held by Insiders
45.30% of the stock of MedAvail is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
40.24% of the stock of MedAvail is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for MedAvail are expected to grow in the coming year, from ($10.11) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MedAvail is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MedAvail is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MedAvail has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

MedAvail (NASDAQ:MDVL) Frequently Asked Questions

Is MedAvail a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MedAvail in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MedAvail stock.
View analyst ratings for MedAvail or view top-rated stocks.

What stocks does MarketBeat like better than MedAvail?

Wall Street analysts have given MedAvail a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MedAvail wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MedAvail's next earnings date?

MedAvail is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for MedAvail.

How were MedAvail's earnings last quarter?

MedAvail Holdings, Inc (NASDAQ:MDVL) released its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.01. MedAvail had a negative trailing twelve-month return on equity of 168.39% and a negative net margin of 245.38%.
View MedAvail's earnings history.

What guidance has MedAvail issued on next quarter's earnings?

MedAvail issued an update on its FY 2021 earnings guidance on Wednesday, May, 12th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $27 million-$31 million, compared to the consensus revenue estimate of $30.03 million.

What price target have analysts set for MDVL?

2 Wall Street analysts have issued 12-month price targets for MedAvail's stock. Their forecasts range from $20.00 to $20.00. On average, they anticipate MedAvail's share price to reach $20.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price.
View analysts' price targets for MedAvail or view top-rated stocks among Wall Street analysts.

Who are MedAvail's key executives?

MedAvail's management team includes the following people:

Mr. Edwin J. Kilroy, Pres, CEO & Director (Age 61, Pay $338.26k)
Mr. William Misloski, Chief Marketing Officer (Age 51, Pay $416k)
Mr. Neil Prezioso, Chief Pharmacy Officer (Age 62, Pay $408.33k)
Mr. Ryan Ferguson, CFO, Treasurer & Sec. (Age 46)
Mr. George Burrows, VP of Operations & Vendor Management
Mr. Fraser Mackay, Chief Information Officer (Age 51)
Ms. Lisa Lutich, VP of HR
Mr. David Rawlins, Chief Commercial Officer (Age 41)

Who are some of MedAvail's key competitors?

Some companies that are related to MedAvail include COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), Innoviva (INVA), Endo International (ENDP), Arcutis Biotherapeutics (ARQT), ImmunoGen (IMGN), Protagonist Therapeutics (PTGX), Northwest Biotherapeutics (NWBO), Antibe Therapeutics (ATBPD), Zealand Pharma A/S (ZEAL), Zymeworks (ZYME), Stoke Therapeutics (STOK), Theravance Biopharma (TBPH), Avid Bioservices (CDMO) and Repare Therapeutics (RPTX).
View all of MDVL's competitors.

What is MedAvail's stock symbol?

MedAvail trades on the NASDAQ under the ticker symbol "MDVL."

Who are MedAvail's major shareholders?

MedAvail's stock is owned by many different retail and institutional investors. Top institutional shareholders include Pura Vida Investments LLC (7.33%), Cigna Investments Inc. New (1.61%), Royce & Associates LP (0.37%), Citigroup Inc. (0.06%), Geode Capital Management LLC (0.04%) and Burleson & Company LLC (0.01%).
View institutional ownership trends for MedAvail.

Which institutional investors are selling MedAvail stock?

MDVL stock was sold by a variety of institutional investors in the last quarter, including Pura Vida Investments LLC.
View insider buying and selling activity for MedAvail or view top insider-selling stocks.

Which institutional investors are buying MedAvail stock?

MDVL stock was acquired by a variety of institutional investors in the last quarter, including Cigna Investments Inc. New, Royce & Associates LP, Geode Capital Management LLC, Citigroup Inc., and Burleson & Company LLC.
View insider buying and selling activity for MedAvail or or view top insider-buying stocks.

How do I buy shares of MedAvail?

Shares of MDVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MedAvail's stock price today?

One share of MDVL stock can currently be purchased for approximately $11.40.

How much money does MedAvail make?

MedAvail has a market capitalization of $364.18 million and generates $1.03 million in revenue each year. The company earns $-4,260,000.00 in net income (profit) each year or ($5.52) on an earnings per share basis.

How many employees does MedAvail have?

MedAvail employs 137 workers across the globe.

What is MedAvail's official website?

The official website for MedAvail is www.medavail.com.

Where are MedAvail's headquarters?

MedAvail is headquartered at 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927.

How can I contact MedAvail?

MedAvail's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at 905-812-0023 or via email at [email protected]

This page was last updated on 5/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here